Allianz Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.6M Sell
47,028
-634
-1% -$191K 0.01% 832
2026
Q1
$15.8M Sell
47,662
-213
-0.4% -$72.5K 0.02% 694
2025
Q4
$19M Sell
47,875
-58,941
-55% -$26.1M 0.02% 622
2025
Q3
$48.7M Sell
106,816
-99,177
-48% -$40.4M 0.05% 342
2025
Q2
$67.2M Sell
205,993
-12,510
-6% -$3.46M 0.08% 238
2025
Q1
$59M Buy
218,503
+109,632
+101% +$28.2M 0.08% 261
2024
Q4
$25.6M Buy
108,871
+82,065
+306% +$21.6M 0.03% 478
2024
Q3
$7.37M Buy
26,806
+8,632
+47% +$2.25M 0.01% 861
2024
Q2
$4.42M Buy
18,174
+6,660
+58% +$1.05M 0.01% 1025
2024
Q1
$1.72M Sell
11,514
-2,275
-16% -$380K ﹤0.01% 1235
2023
Q4
$2.64M Sell
13,789
-662
-5% -$113K ﹤0.01% 1209
2023
Q3
$2.56M Sell
14,451
-2,144
-13% -$409K ﹤0.01% 1320
2023
Q2
$3.15M Sell
16,595
-2,052
-11% -$407K 0.01% 1075
2023
Q1
$3.74M Buy
18,647
+294
+2% +$61.8K 0.01% 1091
2022
Q4
$4.36M Sell
18,353
-3,390
-16% -$723K 0.01% 977
2022
Q3
$4.35M Sell
21,743
-27,968
-56% -$5.33M 0.01% 940
2022
Q2
$7.25M Buy
49,711
+4,783
+11% +$679K 0.01% 989
2022
Q1
$7.34M Sell
44,928
-6,136
-12% -$935K 0.01% 1085
2021
Q4
$8.67M Sell
51,064
-4,490
-8% -$835K 0.01% 1043
2021
Q3
$10.5M Buy
55,554
+20,955
+61% +$3.93M 0.01% 999
2021
Q2
$5.87M Sell
34,599
-2,860
-8% -$419K ﹤0.01% 1050
2021
Q1
$5.29M Buy
37,459
+7,445
+25% +$1.12M 0.01% 1043
2020
Q4
$3.9M Sell
30,014
-1,595
-5% -$213K ﹤0.01% 1127
2020
Q3
$4.6M Sell
31,609
-7,002
-18% -$995K 0.01% 1003
2020
Q2
$5.72M Sell
38,611
-5,214
-12% -$703K 0.01% 1149
2020
Q1
$4.77M Sell
43,825
-14,881
-25% -$1.72M 0.01% 1177
2019
Q4
$6.76M Sell
58,706
-29,211
-33% -$2.91M 0.01% 1344
2019
Q3
$7.09M Sell
87,917
-16,736
-16% -$1.32M 0.01% 1284
2019
Q2
$7.59M Sell
104,653
-19,274
-16% -$1.48M 0.01% 1313
2019
Q1
$11.6M Sell
123,927
-23,886
-16% -$2M 0.01% 1076
2018
Q4
$10.7M Sell
147,813
-26,637
-15% -$2.05M 0.01% 1079
2018
Q3
$15.3M Buy
174,450
+38,720
+29% +$3.89M 0.01% 1054
2018
Q2
$13.4M Buy
135,730
+63,975
+89% +$6.35M 0.01% 1118
2018
Q1
$8.55M Buy
71,755
+100
+0.1% +$12.9K 0.01% 1318
2017
Q4
$9.1M Buy
71,655
+44,655
+165% +$5.61M 0.01% 1363
2017
Q3
$3.17M Sell
27,000
-3,177
-11% -$271K ﹤0.01% 1839
2017
Q2
$2.38M Buy
30,177
+3,177
+12% +$203K ﹤0.01% 1917
2017
Q1
$1.38M Hold
27,000
﹤0.01% 2130
2016
Q4
$1.01M Sell
27,000
-63,574
-70% -$2.66M ﹤0.01% 2208
2016
Q3
$6.3M Sell
90,574
-2,049
-2% -$145K 0.01% 1528
2016
Q2
$5.14M Buy
92,623
+41,020
+79% +$2.58M 0.01% 1502
2016
Q1
$3.24M Buy
51,603
+673
+1% +$44.7K ﹤0.01% 1605
2015
Q4
$4.81M Hold
50,930
0.01% 1369
2015
Q3
$4.09M Sell
50,930
-1,500
-3% -$167K ﹤0.01% 1346
2015
Q2
$6.29M Sell
52,430
-50,880
-49% -$6.08M 0.01% 1299
2015
Q1
$10.8M Buy
103,310
+23,000
+29% +$2.33M 0.01% 928
2014
Q4
$7.79M Buy
80,310
+27,860
+53% +$2.58M 0.01% 1053
2014
Q3
$4.1M Sell
52,450
-2,000
-4% -$129K ﹤0.01% 1157
2014
Q2
$3.44M Buy
54,450
+455
+0.8% +$27K ﹤0.01% 1034
2014
Q1
$3.63M Sell
53,995
-22,000
-29% -$1.7M ﹤0.01% 1030
2013
Q4
$4.89M Sell
75,995
-79,595
-51% -$4.75M 0.01% 953
2013
Q3
$9.96M Buy
155,590
+17,000
+12% +$847K 0.01% 671
2013
Q2
$4.3M Buy
+138,590
New +$3.69M 0.01% 941

Other funds holding ALNY

Allianz Asset Management's ALNY Position: Q2 2026 in Review

Allianz Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.3% in Q2 2026, selling an estimated $191K and leaving 47,028 shares worth $15.6M. The position accounts for 0.01% of the portfolio, ranked #832.

Allianz Asset Management first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $67.2M in Q2 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Allianz Asset Management held 47,028 shares of Alnylam Pharmaceuticals worth $15.6M as of Q2 2026.
  • Allianz Asset Management sold 634 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $191K.
  • Alnylam Pharmaceuticals made up 0.01% of Allianz Asset Management's portfolio in Q2 2026, its #832 holding.
  • Allianz Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Allianz Asset Management's Alnylam Pharmaceuticals position peaked at $67.2M in Q2 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.